Purification of taxanes
A method of crystallizing docetaxel is disclosed. The method comprises (a) combining docetaxel and at least one solubilizing solvent to obtain a solution, wherein the solubilizing solvent is selected from the group consisting of acetone, methyl-tert-butyl ether, tetrahydrofuran (THF), and acetonitrile and (b) adding an anti-solvent to the solution to obtain a crystalline docetaxel, wherein the anti-solvent is water.
1. A method of crystallizing docetaxel comprising:
(a) combining docetaxel and at least one solubilizing solvent to obtain a solution, wherein the solubilizing solvent is selected from methyl-tert-butyl ether, tetrahydrofuran (THF), or acetonitrile; and
(b) adding an anti-solvent to the solution to obtain a crystalline docetaxel, wherein the anti-solvent is water.
2. The method of claim 1 , further comprising recrystallizing the crystalline docetaxel.
3. The method of claim 2 , wherein the recrystallization comprises:
(c) combining the crystalline docetaxel and a solubilizing solvent to obtain a second solution; and
(d) adding an anti-solvent to the second solution.
4. The method of claim 1 , wherein the docetaxel used in step (a) is isolated from a taxane material comprising docetaxel obtained from a semi-synthesis or total synthesis process, the isolation process comprising:
(i) loading or injecting the material on a column comprising a polyethyleneimine-bonded silica (PBS) resin;
(ii) eluting docetaxel from the PBS resin; and
(iii) recovering the eluted docetaxel.
5. The method of claim 4 , wherein molecules used as reactants in the semi-synthetic or total synthetic process are not derived solely from Taxus brevifolia.
6. The method of claim 4 , wherein the material loaded or injected on the column comprises less than about 8% by weight of C-2′ benzoyl primary taxanes.
7. The method of claim 4 , wherein the PBS resin is diethylaminomethyl (DEAM).
8. The method of claim 4 , wherein the PBS resin is polyethyleneimine (PEI).
9. The method of claim 8 , wherein the amino groups of the PEI are functionalized.
10. The method of claim 4 , wherein the PBS resin has an average pore size ranging from about 60 to about 800 Angstrom Units and an average particle size ranging from about 0.25 to about 500 microns.
11. A method of crystallizing docetaxel comprising:
(a) combining docetaxel and at least two solubilizing solvents to obtain a solution, wherein the two solubilizing solvents are tetrahydrofuran (THF) and methanol; and
(b) adding an anti-solvent to the solution to obtain a crystalline docetaxel, wherein the anti-solvent is water.
12. The method of claim 11 , further comprising recrystallizing the crystalline docetaxel.
13. The method of claim 12 , wherein the recrystallization comprises:
(c) combining the crystalline docetaxel and a solubilizing solvent to obtain a second solution; and
(d) adding an anti-solvent to the second solution.
14. The method of claim 11 , wherein the docetaxel used in step (a) is isolated from a taxane material comprising docetaxel obtained from a semi-synthesis or total synthesis process, the isolation process comprising:
(i) loading or injecting the material on a column comprising a polyethyleneimine-bonded silica (PBS) resin;
(ii) eluting docetaxel from the PBS resin; and
(iii) recovering the eluted docetaxel.
15. The method of claim 14 , wherein molecules used as reactants in the semi-synthetic or total synthetic process are not derived solely from Taxus brevifolia.
16. The method of claim 14 , wherein the material loaded or injected on the column comprises less than about 8% by weight of C-2′ benzoyl primary taxanes.
17. The method of claim 14 , wherein the PBS resin is diethylaminomethyl (DEAM).
18. The method of claim 14 , wherein the PBS resin is polyethyleneimine (PEI).
19. The method of claim 18 , wherein the amino groups of the PEI are functionalized.
20. The method of claim 14 , wherein the PBS resin has an average pore size ranging from about 60 to about 800 Angstrom Units and an average particle size ranging from about 0.25 to about 500 microns.
21. A method of crystallizing paclitaxel comprising:
(a) combining paclitaxel and a solubilizing solvent to obtain a solution, wherein the solubilizing solvent is acetone; and
(b) adding an anti-solvent to the solution to obtain a crystalline paclitaxel, wherein the anti-solvent is water, wherein the paclitaxel used in step (a) is isolated from a taxane material comprising paclitaxel obtained from a semi-synthesis or total synthesis process, the isolation process comprising:
(i) loading or injecting the material on a column comprising a polyethyleneimine-bonded silica (PBS) resin;
(ii) eluting paclitaxel from the PBS resin; and
(iii) recovering the eluted paclitaxel.
22. The method of claim 21 , wherein molecules used as reactants in the semi-synthetic or total synthetic process are not derived solely from Taxus brevifolia.
23. The method of claim 21 wherein the material loaded or injected on the column comprises less than about 8% by weight of C-2′ benzoyl primary taxanes.
24. The method of claim 21 , wherein the PBS resin is diethylaminomethyl (DEAM).
25. The method of claim 21 , wherein the PBS resin is polyethyleneimine (PEI).
26. The method of claim 25 , wherein the amino groups of the PEI are functionalized.
27. The method of claim 21 , wherein the PBS resin has an average pore size ranging from about 60 to about 800 Angstrom Units and an average particle size ranging from about 0.25 to about 500 microns.